It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
March 17 (Bloomberg) -- A researcher at a Hamburg laboratory was punctured with a needle that may have contained traces of the deadly Ebola virus and was transferred to an isolation ward following inoculation treatment, the clinic said in a statement.
The university clinic in Hamburg-Eppendorf, which is treating the woman, ruled out any danger to the public, according to the e-mailed statement. Ebola is an animal-borne virus that causes high fever, diarrhea, vomiting and internal bleeding.
The woman, a scientist at the Bernhard-Nocht-Institut for tropical medicine, was punctured through protective clothing while in a high-security laboratory on March 12. Though she showed no signs of infection, a group of experts recommended an inoculation treatment developed in the U.S., the clinic said.
First person to receive vaccine The vaccine arrived in Germany last Friday and was given to the woman the next day, making her the first person to receive this vaccine. The scientist who led the development team praised Canada's quick response.
"It was a tremendous response on the Winnipeg side to get that out the same day and get it over and get this delivered," said Dr. Heinz Feldmann, former head of the special pathogens unit at the Winnipeg lab.
"She got immunized within 40 hours after exposure. And considering that this had to be shipped across the Atlantic, I think that's quite an achievement."
An experimental Ebola vaccine developed in Winnipeg could eventually become the first treatment for people newly infected with the deadly virus. Testing in three types of animals showed the vaccine kept at least half from dying when it was administered after infection, Canadian and American researchers reported in the Jan. 19 issue of the journal Public Library of Science Pathogens. The vaccine aims to tip the balance in favour of the immune system over the virus, said Dr. Steven Jones. (CBC) Most promising was the fact that four of eight primates injected with a lethal dose of Ebola virus survived when they were given the vaccine within 30 minutes of exposure. It is the first time a vaccine against one of the species of Ebola viruses has been shown to be effective in what's called a post-exposure setting. In fact, it's the first time anything has been shown to improve survival after infection with an Ebola virus.
"I don't think this takes us any closer to actually having something," said Dr. Karl Johnson, who headed the special pathogens unit at the U.S. Centers for Disease Control when Ebola first came to the attention of developed countries. Johnson said it would be unacceptable to use the vaccine in Africa — where Ebola outbreaks occur — until it's been shown to be safe and effective elsewhere. Thankfully, lab accidents with filoviruses are exceedingly rare because of the high levels of training and of biosafety required to work with these most horrific of viral killers. It could be years before there was even an opportunity to test the vaccine in a lab accident victim.
Originally posted by deltaalphanovember
From the same article, a bit of oddness. The scientist who named the Ebola virus was resigned to the fact that unless there was a lab accident, this vaccine could never be ethically tested!
Thankfully, lab accidents with filoviruses are exceedingly rare because of the high levels of training and of biosafety required to work with these most horrific of viral killers. It could be years before there was even an opportunity to test the vaccine in a lab accident victim.
Originally posted by deltaalphanovember
reply to post by drsmooth23
I suppose Wacko Jacko's death has more relevance than the potential Ebola cure being tested.
Is Ebola transmitted via the air? In primates the Ebola virus was transmitted through the air in a research facility in Reston, Virginia. Apparently the mutations that allowed the virus to easily transmit via the air also changed its effect on humans. Tests showed that four lab workers tested positive for Ebola Reston virus, but this strain of the virus caused only minor health problems (although all the monkeys in the Reston facility were destroyed to prevent the outbreak from spreading).
here are claims, however, that airborne human to human transmission of Ebola occurred in 1976. Reports say that Mayinga N'Seka (seen as the patient in the image to the right), a nurse in Zaire may have contracted the virus via the air. Evidence is thin, and even if it was true, Nurse Mayinga did not infect any other humans before she died.
Presently, 4 distinct subtypes have been identified, each named for the location where it caused documented human or animal disease. Two Africa subtypes, Ebola virus Zaire (EBO-Z) and Ebola virus Sudan (EBO-S), have been responsible for most of the reported deaths caused by filoviruses. Clinical disease due to African-derived Ebola virus is severe and, with the exception of 2 patients infected with the Ebola virus Côte-d'Ivoire (EBO-C) subtype who survived, is associated with a mortality rate of 65% (Sudan, 1979) to 89% (DRC, Dec 2002 to Apr 2003). The fourth subtype is Ebola virus Reston (EBO-R), which was first isolated in 1989 in monkeys imported from a single Philippine exporter. A virtually identical isolate imported from the same Philippine exporter was detected in 1992 in Siena, Italy.